The Investor
04 Sep 2026, 19:39
Agilent Launches FDA-Cleared S540MD Digital Pathology Scanner in U.S.
Agilent Technologies (NYSE: A) has launched its S540MD Slide Scanner System in the United States following FDA clearance, expanding the company’s presence in the growing digital pathology market.
The S540MD is a whole-slide imaging system designed for high-volume clinical laboratories. It can hold up to 540 slides and supports continuous loading, automated scanning and advanced tissue detection, helping laboratories digitize pathology workflows at scale.
Agilent Targets AI-Enabled Pathology Growth
The launch comes as pathology laboratories increasingly adopt digital and AI-enabled diagnostic workflows to handle rising sample volumes and improve efficiency.
Agilent said the scanner is intended to integrate digital imaging with its existing pathology expertise and staining workflows. The system is an Agilent-branded version of Hamamatsu’s NanoZoomer S540MD scanner.
The U.S. rollout follows the product’s January 2026 introduction in selected European markets. For Agilent, the FDA-cleared launch expands its clinical diagnostics portfolio and positions the company to benefit from increasing adoption of digital pathology and AI-assisted laboratory workflows.
Agilent Technologies (NYSE: A) has launched its S540MD Slide Scanner System in the United States following FDA clearance, expanding the company’s presence in the growing digital pathology market.
The S540MD is a whole-slide imaging system designed for high-volume clinical laboratories. It can hold up to 540 slides and supports continuous loading, automated scanning and advanced tissue detection, helping laboratories digitize pathology workflows at scale.
Agilent Targets AI-Enabled Pathology Growth
The launch comes as pathology laboratories increasingly adopt digital and AI-enabled diagnostic workflows to handle rising sample volumes and improve efficiency.
Agilent said the scanner is intended to integrate digital imaging with its existing pathology expertise and staining workflows. The system is an Agilent-branded version of Hamamatsu’s NanoZoomer S540MD scanner.
The U.S. rollout follows the product’s January 2026 introduction in selected European markets. For Agilent, the FDA-cleared launch expands its clinical diagnostics portfolio and positions the company to benefit from increasing adoption of digital pathology and AI-assisted laboratory workflows.
